Cargando…
Neoadjuvant and Adjuvant Therapy in Operable Pancreatic Cancer: Both Honey and Milk (but No Bread?)
Pancreatic cancer has a dismal prognosis. Resection is the best option for cure, supported by multimodal therapy to treat the systemic disease. While adjuvant therapy has become standard in those who are fit and who can tolerate the given regimen, the concept of perioperative (neoadjuvant) therapy i...
Autor principal: | Søreide, Kjetil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140001/ https://www.ncbi.nlm.nih.gov/pubmed/33439449 http://dx.doi.org/10.1007/s40487-020-00136-y |
Ejemplares similares
-
Call for better response evaluation after neoadjuvant therapy in pancreatic cancer
por: Zaharia, Claudia, et al.
Publicado: (2023) -
Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?
por: Agrafiotis, Apostolos C., et al.
Publicado: (2023) -
Is there a survival benefit of a robotic approach to pancreatoduodenectomy for pancreatic cancer?
por: Kleive, Dyre, et al.
Publicado: (2023) -
Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer
por: Veen, Torhild, et al.
Publicado: (2023) -
Neoadjuvant therapy for resectable pancreatic cancers
por: Inoue, Yosuke, et al.
Publicado: (2022)